Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse

Leukemia

Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib

Haematologica

Massoud R, Flossdorf S, Hanke F, Schroeder T, Bethge W, Zeiser R, Pabst C, Wulf G, Sala E, Hilgendorf I, Scheid C, Edinger M, Stölzel F, Blau IW, Stelljes M, Kobbe G, Platzbecker U, Bittenbring JT, Eder M, Fleischhauer K, Burchert A, Schmid C, Kröger N

doi: 10.3324/haematol.2025.300176

Leukemia

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Am J Hematol

Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, Bergua JM, Calmet FV, Campbell V, Cetin D, Cimino G, Ciotti G, Corbingi A, De Fazio L, Erol HA, Federico V, Gil C, Gulu YM, Malcorra AB, Mariani S, Mazzone C, Mulè A, Musuraca G, Khan A, Norata M, O'Nions J, Palumbo FE, Papayannidis C, Piccioni AL, Rubio MTO, Sanchez-Tovar J, Serin I, Serrao A, Sevindik OG, Sucato G, Urbano MA, Vetro C, Vives S, Rossi M, Martelli MP, Montesinos P, Othman J, Perrone S

doi: 10.1002/ajh.70142

Leukemia

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)

Leukemia

Cusan M, Larkin K, Nicolet D, Jurinovic V, Mrózek K, Batcha AMN, Rothenberg-Thurley M, Schneider S, Sauerland C, Görlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Spiekermann K, Greif PA, Blachly JS, Mims AS, Walker CJ, Walker MC, Oakes CC, Orwick S, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Stone RM, Byrd JC, Metzeler KH, Herold T, Eisfeld AK

doi: 10.1038/s41375-025-02644-0

Leukemia

Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial

Haematologica

Balduzzi A, Glogova E, Peters C, Sedlacek P, Dalle JH, Locatelli F, Meisel R, Burkhardt B, Buechner J, Wachowiak J, Bierings M, Staciuk R, Graphakos S, Güngör T, Yesilipek A, Svec P, Palma J, Krivan G, Diaz-de-Heredia C, Limido F, Ansari M, Kalwak K, Bader P, Ifversen M

doi: 10.3324/haematol.2025.287456

Leukemia

Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse-Risk TP53-Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Ru Y, Chen J, Ferhat AT, Labussière-Wallet H, Gedde-Dahl T, Kröger N, Socié G, Yakoub-Agha I, Eder M, Mielke S, Wu D, Mohty M, Ciceri F, Gorin NC

doi: 10.1002/ajh.70069

Leukemia

Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort

J Natl Cancer Inst

Zheng DJ, Hettinger G, Aftandilian C, Bona K, Caywood EH, Collier AB, Elgarten CW, Gathers C, Ghosh T, Gramatges MM, Henry M, Huang YV, Li Y, Lotterman C, Maloney K, Mian A, Miller TP, Modi A, Mody R, Morgan E, Myers R, Newman H, Ortiz J, Seif AE, Smith C, Stokke J, Wang X, Winick N, Wilkes JJ, Wong V, Aplenc R, Getz KD

doi: 10.1093/jnci/djaf234

Leukemia

Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis

Haematologica

Chang YS, Lee YW, Liu CY, Othman J, Eckardt JN, Zhou Q, Tien FM, Lyu TW, Tsai XC, Lin CC, Chang H, Ko BS, Chou WC, Röllig C, Russell N, Dillon R, Hou HA

doi: 10.3324/haematol.2025.288081

Leukemia

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Haematologica

Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N

doi: 10.3324/haematol.2025.288553

Leukemia

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

Haematologica

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Zeidner JF, Olin RL, Smith CC, Schiller GJ, Curran EK, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF

doi: 10.3324/haematol.2025.288743

Related content

Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)

Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial

Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort

Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy